This Apoptopic Drugs in Oncology Report Focuses Specifically on Breast and Prostate Cancer

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reports/c86619) has announced the addition of “Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer” to their offering.

This is the report for professionals interested to grasp the field of apoptopic drug targets in oncology and at the same time have an extensive R&D overview of breast- and prostate cancer. This extensive 450+ pages report compiles and analyzes Apoptosis, the type of death about whose genetically controlled pathways we know the most, and further gives an in depth analysis in two key oncology areas; Breast- and Prostate cancer

In the report, the author reports on 90 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 114 apoptopic drugs designed for the treatment of 48 different cancer indications.

To fuel the scientific and competitive thinking, the author opens the gate into the presence and relevance of protein-protein interactions between identified targets of apoptopic drugs. No less than 452 protein-protein interactions were recognized among 96 of the 119 included apoptopic drug targets.

This report section by the numbers

• A hundred different tables. Includes more than 1,500 active links to related resources on the Internet
• 114 apoptopic drugs, under development by 87 investigators, are included, covering more than 430 developmental projects in cancer
• 119 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other apoptopic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
• 90 Unique drug target combinations of apoptopic drugs
• 452 protein-protein interactions among apoptopic drug targets
• Extensive pathway analysis of drug targets

Contents:

1 Executive Summary

2 Methodologies

3 Table of Contents

4 Introduction to Apoptotic Drugs in Oncology

5 Apoptopic Drug Compound Types and Sub-cellular Localizations of Targets

6 The Cancer Genome Project and Apoptopic Drug Targets

7 Protein Expression Profiles of Apoptopic Drug Targets in Human

8 Pathway Analysis of Drug Targets of Apoptopic Drugs

9 Protein-Protein Interactions Between Identified Apoptopic Drug Targets

10 Available Biological Structure Data on Apoptopic Drug Targets

11 Drug Target Profiles of Apoptopic Drug Targets in Oncology

12 Apoptopic Drug Target Mix by Development Stage

13 Apoptopic Drug Target Mix by Cancer Indication

14 Apoptopic Drugs and their Targets by Companies

15 Breast Cancer: An Introduction

16 Current Treatment Strategies of Breast cancer

17 Progress in Current Breast Cancer Treatment Strategies

18 Key Therapeutic Strategies for Future Breast Cancer Therapies

19 Competitive Landscape in Breast Cancer Drug Development: The Late Stage Pipeline

20 Current Drug Development for Breast Cancer: The Early Stage Pipeline 20.1 DNA Targeting

21 Prostate Cancer: An Introduction

22 Current Prostate Cancer Treatment Strategies

23 Progress in Current Prostate Cancer Treatment Strategies

24 Key Therapeutic Strategies for Future Prostate Cancer Therapies

25 Competitive Landscape in Prostate Cancer Drug Development: The Late Stage Pipeline

26 Current Prostate Cancer Drug Development: The Early Stage Pipeline

27 Disclaimer

28 Drug Index

29 Company Index

List of Tables

31 List of Boxes

32 List of Figures

Figure 1: Distribution of Compound Types Among Apoptopic Drugs

Figure 2: Primary Sub-cellular Localization of Drug Targets

For more information visit http://www.researchandmarkets.com/reports/c86619